Advertisement

Journal of Gastroenterology

, Volume 53, Issue 1, pp 27–36 | Cite as

Meta-analysis: proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth

  • Tingting Su
  • Sanchuan Lai
  • Allen LeeEmail author
  • Xingkang He
  • Shujie ChenEmail author
Review

Abstract

The use of proton pump inhibitors (PPIs) may potentially predispose to the development of small intestinal bacterial overgrowth (SIBO), but this association is controversial due to conflicting results from studies conducted to date. The aim of this meta-analysis was to evaluate the association between the use of PPIs and the risk of SIBO. We systematically searched the online PubMed, Embase, and Cochrane Library databases and Web of Science for relevant articles published up to November 2016. Two researchers identified and extracted data independent of each other. The pooled analysis was performed using the generic inverse-variance random-effects model. Subgroup and sensitivity analysis were conducted to assess the stability and heterogeneity of the pooled results. The risk of publication bias was evaluated by assessing for funnel plot asymmetry and by Egger’s test and Begg’s test. A total of 19 articles met the eligibility criteria for the meta-analysis, reporting on 7055 subjects. The pooled odds ratio (OR) showed a statistically significant association between increased risk of SIBO and PPI use (OR 1.71, 95% confidence interval 1.20–2.43). Subgroup analyses demonstrated an association between SIBO and PPI use in studies that employed small bowel aspirates culture and glucose hydrogen breath tests (GHBT) as diagnostic tests for SIBO. Our meta-analysis suggests that the use of PPI moderately increases the risk of SIBO, thereby highlighting the need for appropriate prescribing of PPIs.

Keywords

Small intestinal bacterial overgrowth Proton pump inhibitors Irritable bowel syndrome 

Notes

Acknowledgments

This work was supported by the Zhejiang Province Key Science and Technology Innovation Team (2013TD13), the National Natural Science Foundation of China (81472214), and the Zhejiang Provincial Medical and Health Research Plan (2015126452).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

535_2017_1371_MOESM1_ESM.docx (805 kb)
Supplementary material 1 (DOCX 805 kb)

References

  1. 1.
    Corleto VD, Festa S, Di Giulio E, et al. Proton pump inhibitor therapy and potential long-term harm. Curr Opin Endocrinol Diabetes Obes. 2014;21(1):3–8.CrossRefPubMedGoogle Scholar
  2. 2.
    Bartholow M. Top 200 prescription drugs of 2009. Pharmacy Times. 2010. http://www.pharmacytimes.com/publications/issue/2010/may2010/rxfocustopdrugs-0510.
  3. 3.
    Hollingworth S, Duncan EL, Martin JH. Marked increase in proton pump inhibitors use in Australia. Pharmacoepidemiol Drug Saf. 2010;19(10):1019–24.CrossRefPubMedGoogle Scholar
  4. 4.
    Batuwitage BT, Kingham JG, Morgan NE, et al. Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J. 2007;83(975):66–8.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Ramirez E, Lei SH, Borobia AM, et al. Overuse of PPIs in patients at admission, during treatment, and at discharge in a tertiary Spanish hospital. Curr Clin Pharmacol. 2010;5(4):288–97.CrossRefPubMedGoogle Scholar
  6. 6.
    Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ. 2008;336(7634):2–3.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Schnoll-Sussman F, Katz PO. Clinical implications of emerging data on the safety of proton pump inhibitors. Curr Treat Options Gastroenterol. 2017;15(1):1–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Posserud I, Stotzer PO, Bjornsson ES, et al. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut. 2007;56(6):802–8.CrossRefPubMedGoogle Scholar
  9. 9.
    King T. Small intestinal bacterial overgrowth and irritable bowel syndrome. JAMA. 2004;292(18):2213 (author reply 2213–4).PubMedGoogle Scholar
  10. 10.
    Laine L, Ahnen D, McClain C, et al. Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther. 2000;14(6):651–68.CrossRefPubMedGoogle Scholar
  11. 11.
    Fried M, Siegrist H, Frei R, et al. Duodenal bacterial overgrowth during treatment in outpatients with omeprazole. Gut. 1994;35(1):23–6.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Gough A, Andrews D, Bacon PA, et al. Evidence of omeprazole-induced small bowel bacterial overgrowth in patients with scleroderma. Br J Rheumatol. 1995;34(10):976–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Lewis SJ, Franco S, Young G, et al. Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole. Aliment Pharmacol Ther. 1996;10(4):557–61.CrossRefPubMedGoogle Scholar
  14. 14.
    Liang SF, Xu L, Zhang DS, et al. Effect of probiotics on small intestinal bacterial overgrowth in patients with gastric and colorectal cancer. Turk J Gastroenterol. 2016;27(3):227–32.CrossRefPubMedGoogle Scholar
  15. 15.
    Giamarellos-Bourboulis EJ, Pyleris E, Barbatzas C, et al. Small intestinal bacterial overgrowth is associated with irritable bowel syndrome and is independent of proton pump inhibitor usage. BMC Gastroenterol. 2016;16(1):67–73CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Enko D, Kriegshauser G. Functional 13C-urea and glucose hydrogen/methane breath tests reveal significant association of small intestinal bacterial overgrowth in individuals with active Helicobacter pylori infection. Clin Biochem. 2016;50(1-2):46–9.Google Scholar
  17. 17.
    Schatz RA, Zhang Q, Lodhia N, et al. Predisposing factors for positive d-Xylose breath test for evaluation of small intestinal bacterial overgrowth: a retrospective study of 932 patients. World J Gastroenterol. 2015;21(15):4574–82.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Franco DL, Disbrow MB, Kahn A, et al. Duodenal aspirates for small intestine bacterial overgrowth: yield, PPIs, and outcomes after treatment at a Tertiary Academic Medical Center. Gastroenterol Res Pract. 2015;2015:971582.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Senderovky M, Lasa J, Dima G, et al. Influence of proton pump inhibitors on intestinal fermentative profile: a case–control study. Acta Gastroenterol Latinoam. 2014;44(3):205–9.PubMedGoogle Scholar
  20. 20.
    Jacobs C, Coss Adame E, Attaluri A, et al. Dysmotility and proton pump inhibitor use are independent risk factors for small intestinal bacterial and/or fungal overgrowth. Aliment Pharmacol Ther. 2013;37(11):1103–11.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Ratuapli SK, Ellington TG, O’Neill MT, et al. Proton pump inhibitor therapy use does not predispose to small intestinal bacterial overgrowth. Am J Gastroenterol. 2012;107(5):730–5.CrossRefPubMedGoogle Scholar
  22. 22.
    Compare D, Pica L, Rocco A, et al. Effects of long-term PPI treatment on producing bowel symptoms and SIBO. Eur J Clin Invest. 2011;41(4):380–6.CrossRefPubMedGoogle Scholar
  23. 23.
    Choung RS, Ruff KC, Malhotra A, et al. Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture. Aliment Pharmacol Ther. 2011;33(9):1059–67.CrossRefPubMedGoogle Scholar
  24. 24.
    Lombardo L, Foti M, Ruggia O, et al. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol. 2010;8(6):504–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Law D, Pimentel M. Proton pump inhibitor therapy does not affect hydrogen production on lactulose breath test in subjects with IBS. Dig Dis Sci. 2010;55(8):2302–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Majewski M, McCallum RW. Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial. Adv Med Sci. 2007;52:139–42.PubMedGoogle Scholar
  27. 27.
    Pereira SP, Gainsborough N, Dowling RH. Drug-induced hypochlorhydria causes high duodenal bacterial counts in the elderly. Aliment Pharmacol Ther. 1998;12(1):99–104.CrossRefPubMedGoogle Scholar
  28. 28.
    Hutchinson S, Logan R. The effect of long-term omeprazole on the glucose-hydrogen breath test in elderly patients. Age Ageing. 1997;26(2):87–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Thorens J, Froehlich F, Schwizer W, et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut. 1996;39(1):54–9.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Lo WK, Chan WW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol. 2013;11(5):483–90.CrossRefPubMedGoogle Scholar
  31. 31.
    Stewart LA, Clarke M, Rovers M, et al. Preferred reporting items for systematic review and meta-analyses of individual participant data: the PRISMA-IPD statement. JAMA. 2015;313(16):1657–65.CrossRefPubMedGoogle Scholar
  32. 32.
    Wells GA, Shea B, O’Connell D et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute, OttawaGoogle Scholar
  33. 33.
    Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.CrossRefPubMedGoogle Scholar
  34. 34.
    Tsuda A, Suda W, Morita H, et al. Influence of proton-pump inhibitors on the luminal microbiota in the gastrointestinal tract. Clin Transl Gastroenterol. 2015;6:e89.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Freedberg DE, Toussaint NC, Chen SP, et al. Proton pump inhibitors alter specific taxa in the human gastrointestinal microbiome: a crossover trial. Gastroenterology. 2015;149(4):883–5.e9.PubMedGoogle Scholar
  36. 36.
    Ardatskaia MD, Loginov VA, Minushkin ON. Syndrome of bacterial overgrowth in patients with the reduced stomach acid secretion: some aspects of the diagnosis. Eksp Klin Gastroenterol. 2014;12:30–6.Google Scholar
  37. 37.
    Pyleris E, Giamarellos-Bourboulis EJ, Tzivras D, et al. The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome. Dig Dis Sci. 2012;57(5):1321–9.CrossRefPubMedGoogle Scholar
  38. 38.
    Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol. 2000;53(11):1119–29.CrossRefPubMedGoogle Scholar
  39. 39.
    Egger M, Juni P, Bartlett C, et al. How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study. Health Technol Assess. 2003;7(1):1–76.PubMedGoogle Scholar
  40. 40.
    Terrin N, Schmid CH, Lau J, et al. Adjusting for publication bias in the presence of heterogeneity. Stat Med. 2003;22(13):2113–26.CrossRefPubMedGoogle Scholar
  41. 41.
    Peters JL, Sutton AJ, Jones DR, et al. Performance of the trim and fill method in the presence of publication bias and between-study heterogeneity. Stat Med. 2007;26(25):4544–62.CrossRefPubMedGoogle Scholar
  42. 42.
    Nelis GF, Engelage AH, Samson G. Does long-term inhibition of gastric acid secretion with omeprazole lead to small intestinal bacterial overgrowth? Neth J Med. 1994;45(3):93–100.PubMedGoogle Scholar
  43. 43.
    Hawkey CJ, Richter JE, et al., editors. Textbook of clinical gastroenterology and Hepatology. Hoboken: Wiley; 2012.Google Scholar
  44. 44.
    Gasbarrini A, Corazza GR, Gasbarrini G, et al. Methodology and indications of H2-breath testing in gastrointestinal diseases: the Rome consensus conference. Aliment Pharmacol Ther. 2009;29(Suppl 1):1–49.PubMedGoogle Scholar
  45. 45.
    Rana SV, Sharma S, Kaur J, et al. Comparison of lactulose and glucose breath test for diagnosis of small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Digestion. 2012;85(3):243–7.CrossRefPubMedGoogle Scholar
  46. 46.
    Yu D, Cheeseman F, Vanner S. Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS. Gut. 2011;60(3):334–40.CrossRefPubMedGoogle Scholar
  47. 47.
    Chu H, Fox M, Zheng X, et al. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome: clinical characteristics, psychological factors, and peripheral cytokines. Gastroenterol Res Pract. 2016;2016:3230859.PubMedPubMedCentralGoogle Scholar
  48. 48.
    Abbasi MH, Zahedi M, Moghadam SD, et al. Small bowel bacterial overgrowth in patients with irritable bowel syndrome: the first study in iran. Middle East. J Dig Dis. 2015;7(1):36–40.Google Scholar
  49. 49.
    Moraru IG, Moraru AG, Andrei M, et al. Small intestinal bacterial overgrowth is associated to symptoms in irritable bowel syndrome. Evidence from a multicentre study in Romania. Rom J Intern Med. 2014;52(3):143–50.PubMedGoogle Scholar
  50. 50.
    Spiegel BM, Chey WD, Chang L. Bacterial overgrowth and irritable bowel syndrome: unifying hypothesis or a spurious consequence of proton pump inhibitors? Am J Gastroenterol. 2008;103(12):2972–6.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Talley NJ, Dennis EH, Schettler-Duncan VA, et al. Overlapping upper and lower gastrointestinal symptoms in irritable bowel syndrome patients with constipation or diarrhea. Am J Gastroenterol. 2003;98(11):2454–9.CrossRefPubMedGoogle Scholar
  52. 52.
    Locke GR 3rd, Zinsmeister AR, Fett SL, et al. Overlap of gastrointestinal symptom complexes in a US community. Neurogastroenterol Motil. 2005;17(1):29–34.CrossRefPubMedGoogle Scholar
  53. 53.
    Ford AC, Spiegel BM, Talley NJ, et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2009;7(12):1279–86.CrossRefPubMedGoogle Scholar
  54. 54.
    Nucera G, Gabrielli M, Lupascu A, et al. Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2005;21(11):1391–5.CrossRefPubMedGoogle Scholar
  55. 55.
    Yakoob J, Abbas Z, Khan R, et al. Small intestinal bacterial overgrowth and lactose intolerance contribute to irritable bowel syndrome symptomatology in Pakistan. Saudi J Gastroenterol. 2011;17(6):371–5.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Sachdeva S, Rawat AK, Reddy RS, et al. Small intestinal bacterial overgrowth (SIBO) in irritable bowel syndrome: frequency and predictors. J Gastroenterol Hepatol. 2011;26[Suppl 3]:135–8.CrossRefPubMedGoogle Scholar
  57. 57.
    Ghoshal UC, Kumar S, Mehrotra M, et al. Frequency of small intestinal bacterial overgrowth in patients with irritable bowel syndrome and chronic non-specific diarrhea. J Neurogastroenterol Motil. 2010;16(1):40–6.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Washio E, Esaki M, Maehata Y, et al. Proton pump inhibitors increase incidence of nonsteroidal anti-inflammatory drug-induced small bowel injury: a randomized placebo-controlled trial. Clin Gastroenterol Hepatol. 2016;14(6):809–15.CrossRefPubMedGoogle Scholar
  59. 59.
    Watanabe T, Tanigawa T, Nadatani Y, et al. Risk factors for severe nonsteroidal anti-inflammatory drug-induced small intestinal damage. Dig Liver Dis. 2013;45(5):390–5.CrossRefPubMedGoogle Scholar
  60. 60.
    Juillerat P, Schneeweiss S, Cook EF, et al. Drugs that inhibit gastric acid secretion may alter the course of inflammatory bowel disease. Aliment Pharmacol Ther. 2012;36(3):239–47.CrossRefPubMedGoogle Scholar
  61. 61.
    Shah R, Richardson P, Yu H, et al. Gastric acid suppression is associated with an increased risk of adverse outcomes in inflammatory bowel disease. Digestion. 2017;95(3):188–93.CrossRefPubMedGoogle Scholar
  62. 62.
    Otani K, Tanigawa T, Watanabe T, et al. Microbiota plays a key role in non-steroidal anti-inflammatory drug-induced small intestinal damage. Digestion. 2017;95(1):22–8.CrossRefPubMedGoogle Scholar
  63. 63.
    Wallace JL, Syer S, Denou E, et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology. 2011;141(4):1314–22, 1322 e1–5.PubMedGoogle Scholar
  64. 64.
    Muraki M, Fujiwara Y, Machida H, et al. Role of small intestinal bacterial overgrowth in severe small intestinal damage in chronic non-steroidal anti-inflammatory drug users. Scand J Gastroenterol. 2014;49(3):267–73.CrossRefPubMedGoogle Scholar
  65. 65.
    Castiglione F, Del Blanco GDV, Rispo A, et al. Orocecal transit time and bacterial overgrowth in patients with Crohn’s disease. J Clin Gastroenterol. 2000;31(1):63–6.CrossRefPubMedGoogle Scholar
  66. 66.
    Rana SV, Sharma S, Malik A, et al. Small intestinal bacterial overgrowth and orocecal transit time in patients of inflammatory bowel disease. Dig Dis Sci. 2013;58(9):2594–8.CrossRefPubMedGoogle Scholar
  67. 67.
    Greco A, Caviglia GP, Brignolo P, et al. Glucose breath test and Crohn’s disease: diagnosis of small intestinal bacterial overgrowth and evaluation of therapeutic response. Scand J Gastroenterol. 2015;50(11):1376–81.CrossRefPubMedGoogle Scholar

Copyright information

© Japanese Society of Gastroenterology 2017

Authors and Affiliations

  1. 1.Department of Gastroenterology, Sir Run Run Shaw HospitalZhejiang University School of MedicineHangzhouChina
  2. 2.Institute of GastroenterologyZhejiang UniversityHangzhouChina
  3. 3.Division of Gastroenterology and Hepatology, Department of MedicineUniversity of Michigan HospitalAnn ArborUSA

Personalised recommendations